$-0.25 EPS Expected for Spectrum Pharmaceuticals, Inc. (SPPI)
March 4, 2018 – By Adrian Mccoy
Investors sentiment increased to 2.84 in 2017 Q3. Its up 1.89, from 0.95 in 2017Q2. It improved, as 13 investors sold Spectrum Pharmaceuticals, Inc. shares while 19 reduced holdings. 38 funds opened positions while 53 raised stakes. 71.60 million shares or 29.39% more from 55.33 million shares in 2017Q2 were reported.
Jane Street Group Inc Ltd Limited Liability Company stated it has 10,774 shares. Fisher Asset Mngmt Limited Liability Co has 179,209 shares for 0% of their portfolio. New York State Teachers Retirement Sys holds 88,795 shares or 0% of its portfolio. Price T Rowe Assocs Inc Md stated it has 26,016 shares. Legal General Gru Public Ltd Liability Corp owns 138,951 shares. Metropolitan Life Ins holds 58,400 shares or 0.01% of its portfolio. 5,030 were reported by First Mercantile Trust Co. Consonance Cap Limited Partnership holds 13.55% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) or 8.71 million shares. Vanguard holds 0% or 7.00 million shares in its portfolio. Geode Cap Limited Co holds 0% or 654,717 shares. Amer Int Gru holds 0% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) or 61,452 shares. Moreover, Profund Ltd Liability Corp has 0.01% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Arizona State Retirement has 0.01% invested in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI). Swiss Bankshares invested in 0% or 134,200 shares. Renaissance Technology Ltd Liability Company reported 0.11% in Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI).
Analysts expect Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) to report $-0.25 EPS on March, 14.They anticipate $0.03 EPS change or 13.64 % from last quarter’s $-0.22 EPS. After having $-0.22 EPS previously, Spectrum Pharmaceuticals, Inc.’s analysts see 13.64 % EPS growth. The stock increased 3.36% or $0.7 during the last trading session, reaching $21.56. About 817,930 shares traded. Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) has declined 20.03% since March 4, 2017 and is downtrending. It has underperformed by 36.73% the S&P500.
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Ratings Coverage
Among 6 analysts covering Spectrum Pharma (NASDAQ:SPPI), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Spectrum Pharma had 11 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Thursday, August 24 by Jefferies. The firm has “Outperform” rating by RBC Capital Markets given on Friday, August 7. The rating was maintained by Jefferies on Wednesday, June 7 with “Buy”. Zacks upgraded it to “Hold” rating and $8.25 target in Thursday, August 27 report. Jefferies maintained Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) rating on Monday, October 9. Jefferies has “Buy” rating and $18 target. The rating was reinitiated by H.C. Wainwright on Wednesday, August 16 with “Buy”. The firm has “Outperform” rating given on Thursday, November 5 by RBC Capital Markets. Jefferies maintained the shares of SPPI in report on Friday, February 10 with “Buy” rating.
Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company has market cap of $2.15 billion. The firm markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It currently has negative earnings. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer.
More notable recent Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) news were published by: Seekingalpha.com which released: “Spectrum Pharmaceuticals: Continued Upside In 2018” on February 25, 2018, also Seekingalpha.com with their article: “Spectrum Pharmaceuticals: What’s Next For Poziotinib” published on February 28, 2018, Seekingalpha.com published: “Spectrum Pharmaceuticals: What The Positive ADVANCE Study Entails?” on February 07, 2018. More interesting news about Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) were released by: Businesswire.com and their article: “Spectrum Pharmaceuticals Announces Appointment of William L. Ashton to its …” published on February 27, 2018 as well as Reuters.com‘s news article titled: “BRIEF-Spectrum Pharmaceuticals Announces Appointment Of William Ashton To Its …” with publication date: February 27, 2018.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.